Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase <b>(</b> PI3K) inhibitors reduce vascular inflammation <i>in vitro</i> and <i>in vivo</i>
Selective p110α inhibition of vascular inflammation may provide a novel therapeutic pathway for limiting adverse tissue swelling. Moreover, the limited effect of BYL-719 on C5a-mediated responses implies that this innate component of the immune response will continue to provide essential defence activity during p110α blockade.
Authors
- Fulye Argunhan (ORCID: https://orcid.org/0000-0001-7616-2151)
- Xenia Kodji (ORCID: https://orcid.org/0000-0002-5822-685X)
- Silvia Cellone Trevelin (ORCID: https://orcid.org/0000-0003-2722-2458)
- Hiba Chaudhry (ORCID: https://orcid.org/0000-0002-8549-215X)
- Camilla Cerutti (ORCID: https://orcid.org/0000-0001-9426-686X)
- Anne J. Ridley
- Susan D. Brain (ORCID: https://orcid.org/0000-0002-9684-8342)
- Ajay M. Shah (ORCID: https://orcid.org/0000-0002-6547-0631)
- Ali A. Zarban (ORCID: https://orcid.org/0000-0003-0328-5032)
- Xiao‐Qing Xiong (ORCID: https://orcid.org/0009-0008-4717-6499)
Institutions
- Agency for Science, Technology and Research (SG)
- King's College London (GB)
- University of Bristol (GB)
- Nanjing Medical University (CN)
- Jazan University (SA)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1111/bph.70152
- Primary Topic
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jazan University
- British Heart Foundation